Jul 27, 2020

Kelly Roman is the cofounder and CEO of Fisher Wallace Laboratories. Since 2007, their revolutionary Stimulator device helps all types of patients cope with mental illness through brain stimulation. In this episode, Mr. Roman emphasizes maintaining science as a priority while building a sustainable business. 

Top three takeaways:

1. The biomarker studies completed using the Fisher Wallace Stimulator have shown increases in serotonin and endorphins with a  decrease in cortisol and stress hormone. 
2. The Stimulator has a 70-75% success rate with almost no side effects. 
3. With a low maximum output and safe product placement variability, the Stimulator is a very user-friendly device. 

[0:00] Ladan introduces the episode and the guest, Kelly Roman. 

[1:30] Roman discusses the beginnings of how the Fisher Wallace Stimulator came to be.  

[4:15] A Mount Sinai study showed that compared to patients given a placebo device, those using the Fisher Wallace Stimulator saw improvement in their mental illness symptoms. 

[6:30] Alternating current used in the stimulator allows for brainwave entrainment, which leaves the brain in the desired brainwave state even after stimulation has stopped. 

[8:25] Patients are reporting 70-75% success rate when treating at  least one symptom. 

[11:30] The next step for the company is to compile MRI and imagery data using the device.

[14:00]  The Stimulator device is inexpensive due to highly effective commercialization and lack of needed doctor administration. 

[16:25] For safety, there is a low output current that still maintains clinical effects. 

[19:20] Roman explains the process of acquiring the intellectual property for the device and the company’s beginnings. 

[21:50]  Due to Roman’s digital marketing experience and many prominent drugs becoming generic, sales for Fisher Wallace’s  new device went well.